 PETAH TIKVA, Israel, Dec. 03, 2020 GLOBE NEWSWIRE -- PolyPid Ltd. Nasdaq: PYPD, a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will host a key opinion leader KOL call on D-PLEX100 for the prevention of surgical site infections on Tuesday, December 15, 2020, at 8:00 am Eastern Time. 